To do that, we performed ChIP analysis on vehicle and CB-treated breast cancer cells using primers spanning the promoter regions of cyclin E, which is a known target of HMGA1 and showed reduced expression in CB-treated breast cancer cells. This evidence concerns the gene CCNE1 and breast carcinoma.